CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
MWN-AI** Summary
Cannabis Bioscience International Holdings, Inc. (CBIH), trading on the OTC Markets, has launched its initiative called Evidence Sprint 2026, aimed at converting cannabinoid science into actionable medical evidence. This program focuses on developing protocols, operational collaborations, and grant-ready projects to enhance the credibility of cannabinoid-derived therapies. A key component of this strategy is the company's engagement with the Centers for Medicare & Medicaid Services (CMS), particularly in discussions with Administrator Dr. Mehmet Oz. This outreach reflects CBIH's commitment to fostering institutional dialogue centered on medical applications of cannabinoids.
In its pursuit of advancing research, CBIH is working to transition from mere interest to concrete action. This involves deepening connections with pharmaceutical companies, healthcare institutions, and legislative bodies, ultimately aiming for practical implementation and measurable outcomes. Amidst a changing financial landscape where federal regulations are evolving, CBIH is positioned to leverage grants and funding for cannabinoid-related research. Notably, the California Department of Cannabis Control has allocated significant funding towards academic projects in this field, underscoring a broader trend of increased financial support for cannabinoid research.
CBIH's approach is methodical, focusing on verifiable science encompassing formulation, delivery methods, and safety measures. Dr. Rosangel Andrades, CBIH's R&D Director, emphasizes that their efforts are not just for publicity but are geared towards producing reliable, clinically sound data. The company prioritizes forming strategic alliances with institutional partners to elevate research standards and deliver therapeutic developments that benefit patients and healthcare professional alike. With a diverse patent portfolio in various therapeutic areas including oncology, neurology, and endocrinology, CBIH is positioned to make impactful contributions within the medical cannabis landscape.
MWN-AI** Analysis
Cannabis Bioscience International Holdings, Inc. (CBIH) recently announced its "Evidence Sprint 2026," focusing on transforming cannabinoid science into clinically-useful medical evidence. This initiative, supported by a formal communication from the Centers for Medicare & Medicaid Services (CMS) regarding a meeting with Dr. Mehmet Oz, suggests CBIH is strategically positioning itself at the intersection of healthcare, regulatory compliance, and community engagement.
For investors, CBIH appears to be executing a well-thought-out plan aimed at attracting funding through a robust grant-seeking strategy, as indicated by previous successes, such as nearly $30 million awarded for cannabis research in California. This momentum aligns with broader trends in normalization within the cannabis sector, where increasing regulatory clarity and institutional interest can extend beyond public sentiment into actionable healthcare initiatives.
Furthermore, CBIH's approach to increasing dialogue around cannabinoid therapies and engaging with multiple sectors highlights their intent to transition from a potentially volatile interest landscape to concrete operational projects. The company's distinct emphasis on collaboration with institutions, academia, and pharmaceutical entities enhances its credibility and establishes CBIH as a stakeholder capable of influencing the therapeutic landscape effectively.
From a financial perspective, CBIH could represent a speculative buy opportunity. However, investors should consider the typical volatility associated with OTC stocks, especially in emerging sectors like cannabis. Monitoring legislative progress, such as the SAFER Banking Act, will be critical, as these developments could enhance operational viability and stimulate market demand.
In conclusion, CBIH's alignment with scientific rigor and institutional collaboration, combined with increasing funding opportunities, presents a forward-looking investment opportunity. Caution is advised, however; potential investors should weigh the inherent risks associated with the cannabis market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding.
CBIH confirms receipt of a communication from the Centers for Medicare & Medicaid Services (CMS) acknowledging Company's meeting request with CMS Administrator Dr. Mehmet Oz and placing the request within the formal institutional coordination channel, with an update expected as the internal process progresses. For CBIH, this step strengthens a strategic opportunity: to elevate public and institutional dialogue with a medical focus, advance evidence-based education, and promote serious standards for the responsible development of cannabinoid-derived therapies.
In parallel, CBIH is executing a multi-sector offensive to turn conversation into action through formal communications, calls, and direct coordination with pharmaceutical companies, healthcare organizations, institutional teams, and legislative offices, with a clear goal: moving from "interest" to technical working sessions and from "intention" to verifiable work plans.
On the financial front, the market is entering a phase of progressive normalization: as the federal framework evolves, more institutions and compliance teams are reassessing and building capabilities to serve the ecosystem under more structured risk and control models. In parallel, legislative initiatives such as the SAFER Banking Act continue to point toward greater clarity for financial services in the sector, reinforcing momentum toward broader integration.
"This is not about headlines; it is about evidence that withstands clinical and institutional review," said Rosangel Andrades, MD, CBIH R&D Director. "Our focus is to execute verifiable science: formulation, safety, delivery methods, and measurable outcomes, supported by compliance and real collaboration."
On the funding side, CBIH reported that it is giving full priority to its grants agenda through a pipeline-and-execution approach: identifying calls, aligning eligibility, structuring competitive proposals, and activating institutional partners. This momentum aligns with a tangible trend: meaningful funding is already being allocated to research and education related to medical cannabis and cannabinoids. For example, the California Department of Cannabis Control awarded nearly $30 million in competitive grants to nine academic institutions for 22 projects, marking the third round of this program and bringing the total to nearly $80 million since 2020.
"CBIH is in execution mode: institutions, grants, and evidence," said Jennifer Salguero, Biologist, PhD in Science, Chief Patent Officer, CBIH in Science, University of São Paulo, Brazil. "Our goal is to raise the standard and turn the therapeutic potential of cannabinoids into strong, responsible research that is useful for patients, physicians, and institutions."
CBIH reiterated that its platform integrates investigational formulations, a standardization-oriented vision, and a strategic approach focused on strengthening alliances with institutions and healthcare stakeholders that prioritize rigor, compliance, and outcomes, with a summary of its completed patent portfolio included in the table attached hereto.
| Therapeutic Area | Percentage (%) | Number | Disease/ Medical condition | Patent Application Summary |
| Neurology / Psychiatry | 40.91 | 9 | Depression | Advanced cannabinoid therapeutic composition targeting the microbiota-gut-brain axis for comprehensive depression management. |
| Anxiety | Comprehensive cannabinoid compositions and methods for managing anxiety disorders. | |||
| Multiple Sclerosis | Advanced cannabinoid formulation for targeted management of multiple sclerosis. | |||
| PTSD | Therapeutic method utilizing cannabinoids and natural compounds for post-traumatic stress disorder (PTSD). | |||
| Dementia/ Alzheimer | Nanoemulsion-based intranasal therapeutic formulation for treating Alzheimer's disease using neuroactive natural compounds. | |||
| Shingles | Integrative treatment for shingles based on cannabinoid compounds (neuropathic component). | |||
| Acute Pain | Acute pain management using cannabis-derived compounds. | |||
| CBDNopioid | Use of Cannabinoids for Reducing Opioid Dependence | |||
| Autism | In progress | |||
| Oncology | 13.64 | 3 | Pancreatic Cancer | Method of treatment for pancreatic cancer. |
| Breast Cancer | Cannabinoid-based nanoplatform composition and methods for treating breast cancer by inhibiting VEGF. | |||
| Sarcoma de Ewing | Nanoemulsion-based therapeutic composition of cannabinoids and natural compounds for the treatment of Ewing sarcoma. | |||
| Endocrinology / Metabolic Diseases | 13.64 | 3 | Diabetes | Oral liquid oil-in-water nanoemulsion comprising phytocannabinoids and bioactive natural compounds for metabolic regulation and management of type 2 diabetes mellitus. |
| Menopause | Cannabinoid-based nanoplatform composition and methods for treating menopause symptoms. | |||
| Infertility +35 | Optimized nanoemulsion delivery of antioxidants, cannabinoids, and nutraceuticals for age-related female fertility decline. | |||
| Rheumatology / Musculoskeletal | 9.09 | 2 | Osteoarthritis | Cannabinoid-based nanoplatform composition and methods for treating knee osteoarthritis. |
| Collagen deficiency | Nanoemulsion cannabinoid gummies promote collagen production and reduce symptoms related to collagen deficiency. | |||
| Gastroenterology / Microbiome Medicine | 4.55 | 1 | Dysbiosis | Edible composition for the prevention and treatment of dysbiosis and gut-related disorders. |
| Ophthalmology | 4.55 | 1 | Glaucoma | Sustained-release ophthalmic composition for targeted treatment of glaucoma and optic nerve degeneration. |
| Dentistry / Oral Medicine | 4.55 | 1 | Oral Care | Cannabinoid formulations and methods for oral care and health management. |
| Infections | 4.55 | 1 | Respiratory Viral Infections | Cannabinoid Composition and Method for Treating Symptoms of Respiratory Viral Infections |
| Gynecology / Sexual Medicine | 4.55 | 1 | Sexual dysfunction-related issues | Polymer-based cannabinoid gel composition and methods for intimate lubrication. |
| Total | 100.00 | 22 |
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information, contact us at:
(214) 733-0868
[email protected]
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.x.com/CBIHIR/
Instagram: www.instagram.com/CBIHSTOCK
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279973
FAQ**
How might the initiatives of Cannabis Bioscience International Holdings Inc (CBIH) impact the cannabis industry landscape in Houston, Texas, especially concerning medical research and compliance?
What role could Houston-based healthcare organizations play in CBIH's strategy to advance evidence-based education and the development of cannabinoid-derived therapies?
How is the local economic environment in Houston, Texas, influencing funding opportunities and collaborations for companies like Cannabis Bioscience International Holdings Inc (CBIH) in the cannabis sector?
What potential changes in regulatory frameworks or public attitudes towards cannabis in Houston could arise from CBIH's advancements in cannabinoid science and evidence-based therapeutics?
**MWN-AI FAQ is based on asking OpenAI questions about Cannabis Bioscience International Holdings Inc (OTC: CBIH).
NASDAQ: CBIH
CBIH Trading
-20.0% G/L:
$0.0004 Last:
802,000 Volume:
$0.0004 Open:
